Duriez P - Search Results

1

Apolipoprotein-AI-containing particles and atherosclerosis.

Fruchart JC, Castro G, Duriez P. Fruchart JC, et al. Among authors: duriez p. Isr J Med Sci. 1996 Jun;32(6):498-502. Isr J Med Sci. 1996. PMID: 8682658 No abstract available.

2

Apolipoprotein A-II, HDL metabolism and atherosclerosis.

Tailleux A, Duriez P, Fruchart JC, Clavey V. Tailleux A, et al. Among authors: duriez p. Atherosclerosis. 2002 Sep;164(1):1-13. doi: 10.1016/s0021-9150(01)00751-1. Atherosclerosis. 2002. PMID: 12119188 Review.

3

[The important role of apolipoprotein C-III in lipoprotein metabolism].

Fruchart JC, Duriez P. Fruchart JC, et al. Among authors: duriez p. C R Seances Soc Biol Fil. 1995;189(5):889-97. C R Seances Soc Biol Fil. 1995. PMID: 8673634 Review. French.

4

HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials?

Fruchart JC, Duriez P. Fruchart JC, et al. Among authors: duriez p. Curr Atheroscler Rep. 2002 Nov;4(6):403-4. doi: 10.1007/s11883-002-0041-3. Curr Atheroscler Rep. 2002. PMID: 12361484 No abstract available.

5

Peroxisome proliferator activated receptors and stroke.

Fruchart JC, Bordet R, Duriez P. Fruchart JC, et al. Among authors: duriez p. Curr Atheroscler Rep. 2003 Sep;5(5):331-2. doi: 10.1007/s11883-003-0001-6. Curr Atheroscler Rep. 2003. PMID: 12911841 No abstract available.

6

Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.

Briand O, Nizard FM, David-Dufilho M, Six I, Lestavel S, Brunet A, Fruchart JC, Torpier G, Bordet R, Clavey V, Duriez P. Briand O, et al. Among authors: duriez p. Biochim Biophys Acta. 2004 Jul 5;1683(1-3):69-77. doi: 10.1016/j.bbalip.2004.04.007. Biochim Biophys Acta. 2004. PMID: 15238221

7

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Fruchart JC, Duriez P. Fruchart JC, et al. Among authors: duriez p. Drugs Today (Barc). 2006 Jan;42(1):39-64. doi: 10.1358/dot.2006.42.1.963528. Drugs Today (Barc). 2006. PMID: 16511610 Review.

8

Apolipoprotein B polymorphism and altered apolipoprotein B concentrations in Congolese blacks.

Parra HJ, Martin F, Monard F, Ngangoué N, Copin N, Bard JM, Qafli M, Vu Dac N, Duriez P, Fruchart JC. Parra HJ, et al. Among authors: duriez p. Clin Genet. 1991 Oct;40(4):263-70. doi: 10.1111/j.1399-0004.1991.tb03094.x. Clin Genet. 1991. PMID: 1756599

9

Apolipoprotein B immunochemical heterogeneity in dialysed patients with chronic renal failure and patients with coronary artery stenosis.

Reade R, Equagoo V, Cachera C, Duriez P, Dracon M, Bard JM, Fievet C, Bertrand M, Tacquet A, Fruchart JC. Reade R, et al. Among authors: duriez p. Am J Nephrol. 1989;9(2):110-4. doi: 10.1159/000167948. Am J Nephrol. 1989. PMID: 2472744

10

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.

Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, Duriez P. Bard JM, et al. Among authors: duriez p. Metabolism. 1995 Nov;44(11):1447-54. doi: 10.1016/0026-0495(95)90145-0. Metabolism. 1995. PMID: 7476333 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters